SCHEMBL16214939

SCHEMBL16214939

[N-]=[N+]=N[C@]1(COC(=O)c2ccccc2)O[C@@H](n2ccc(NC(=O)c3ccccc3)nc2=O)[C@H](OC(=O)c2ccccc2)[C@@H]1OC(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.47
▸ P2RY6 Q15077 4/20 0.46
▸ P2RY14 Q15391 2/20 0.46
▸ NT5E P21589 1/20 0.46
▸ ABL1 P00519 1/20 0.43
▸ RIN1 Q13671 1/20 0.43
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ USP2 O75604 1/20 0.34
▸ P2RY12 Q9H244 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ P2RY4 P51582 3/20 0.32
▸ P2RY2 P41231 2/20 0.32
▸ ST6GAL1 P15907 1/20 0.31
▸ USP30 Q70CQ3 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15281797 1.00 POLB (0.47) POLBP2RY6P2RY14NT5EABL1
SCHEMBL15281846 0.91 POLB (0.47) POLBP2RY6P2RY14NT5EABL1
SCHEMBL16377131 0.91 POLB (0.47) POLBP2RY6P2RY14NT5EABL1
SCHEMBL16870442 0.88 POLB (0.35) POLBP2RY6P2RY14NT5EMEN1
SCHEMBL16214936 0.88 POLB (0.35) POLBP2RY6P2RY14NT5EMEN1
SCHEMBL16214084 0.85 POLB (0.47) POLBP2RY6P2RY14NT5EABL1
SCHEMBL16214102 0.85 POLB (0.47) POLBP2RY6P2RY14NT5EABL1
SCHEMBL13592887 0.83 MAPT (0.37) POLBP2RY6P2RY14NT5EMEN1
SCHEMBL16373883 0.83 POLB (0.49) POLBP2RY6P2RY14NT5EABL1
SCHEMBL19590453 0.83 POLB (0.51) POLBP2RY6P2RY14NT5EABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264610-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC (US) 2016-09-15 — — US disclosed
US-8877731-B2 Azido nucleosides and nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264610-A1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS PNP, ADA, ADAR POLB 954/4885P2RY6 100/4885P2RY14 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback